AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol 265: R934-R942, 1993;
0363-6119/93 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Naitoh, M.
Right arrow Articles by Saruta, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Naitoh, M.
Right arrow Articles by Saruta, T.

AJP - Regulatory, Integrative and Comparative Physiology, Vol 265, Issue 4 934-R942, Copyright © 1993 by American Physiological Society

ARTICLES

Arginine vasopressin produces renal vasodilation via V2 receptors in conscious dogs

M. Naitoh, H. Suzuki, M. Murakami, A. Matsumoto, A. Ichihara, H. Nakamoto, Y. Yamamura and T. Saruta
Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.

In conscious dogs, 36-h water deprivation induced a significant increase in renal blood flow (RBF) with elevation of the plasma arginine vasopressin (AVP) concentration to 9.6 +/- 1.8 pg/ml. To simulate such a condition, a mild elevation of plasma AVP was produced by infusing AVP intravenously at a dose of 0.1 ng.kg-1.min-1 for 20 min. The plasma AVP concentration then increased to 6.8 +/- 0.7 pg/ml. This dose of AVP increased the RBF by 21.7 +/- 2.6% and decreased the renal vascular resistance by 18.1 +/- 2.3% without significant changes in mean arterial pressure, cardiac output, or heart rate. The mechanism of this renal vasodilatory action was examined using newly developed, orally effective, selective AVP antagonists OPC-21268 (a V1-receptor antagonist) and OPC-31260 (a V2-receptor antagonist). In 36-h water-deprived dogs, V2-receptor blockade with OPC-31260 significantly decreased the RBF by 20.5 +/- 2.6% without significant changes in cardiac output. The exogenous AVP-induced renal vasodilatory response tended to be augmented when V1 receptors were blocked by pretreatment with OPC-21268, but the change did not achieve statistical significance. On the other hand, V2-receptor blockade by either pretreatment with OPC-31260 or simultaneous infusion of OPC-31260 inhibited this vasodilatory response. Furthermore, intravenous infusion of 1-desamino-8-D-arginine vasopressin (DDAVP) at a dose of 0.3 ng.kg-1 x min-1 for 20 min significantly increased the RBF by 36.5 +/- 1.7%, and this DDAVP-induced renal vasodilation was inhibited by simultaneous infusion of V2-receptor antagonist.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
L. Bankir, M. Ahloulay, P. N. Devreotes, and C. A. Parent
Extracellular cAMP inhibits proximal reabsorption: are plasma membrane cAMP receptors involved?
Am J Physiol Renal Physiol, March 1, 2002; 282(3): F376 - F392.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. R. Cooke, B. M. Wall, K. M. Huch, and T. Mangold
Cardiovascular effects of vasopressin following V1 receptor blockade compared to effects of nitroglycerin
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2001; 281(3): R887 - R893.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
F. Park, A.-P. Zou, and A. W. Cowley Jr
Arginine Vasopressin–Mediated Stimulation of Nitric Oxide Within the Rat Renal Medulla
Hypertension, November 1, 1998; 32(5): 896 - 901.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online